The Guidelines for the Diagnosis, Treatment and Prevention of Leprosy provide state-of-the-art knowledge and evidence on leprosy diagnosis, treatment and prevention based on a public health approach in endemic countries. The target audience of this document includes policy-makers in leprosy or infec...tious diseases in the ministries of health (especially but not limited to endemic countries), nongovernmental organizations, clinicians, pharmaceutical companies, donors and affected persons
more
Training of Health-care Providers and Training manual Supporting material
Empowering Health Workers to Improve Service Delivery. This training program is designed to build the capacity of program managers and health providers in quality management, and improve the provision of high-quality health services.
Please download the chapters directly from the website: https://w...ww.usaidassist.org/resources/kenya-quality-model-health-training-course-health-sector
more
Le présent document donne des lignes directrices provisoires afin de garantir l’efficacité des communications sur les risques relatives à la transmission du virus Zika et aux complications potentielles. Le lien de causalité entre l’infection à virus Zika et ces complications potentielles n...a pas encore été prouvé. Malgré ces incertitudes, des stratégies de communication efficaces devraient être mises en œuvre afin de permettre aux gens de prendre les meilleures décisions éclairées pour se protéger et protéger leurs familles et leurs communautés. Les présentes lignes directrices sont destinées à être utilisées par les responsables, le personnel et les bénévoles chargés de la communication sur les risques et la santé à l’échelle mondiale, régionale ou nationale; les professionnels de la communication; les anthropologues; les sociologues; les agents de santé; les administrateurs des hôpitaux; les responsables communautaires; les gestionnaires de programme et les décideurs politiques.
more
This document updates the 2009 ECDC guidance on chlamydia control in Europe. It was developed by a technical expert group which conducted a critical review of the scientific evidence on the epidemiology of chlamydia and the effectiveness of screening programmes.
The aim of this guidance is to suppo...rt Member States to develop, implement or improve strategies for chlamydia control. This guidance describes the current evidence base behind the proposed options, highlights key gaps in knowledge, and suggests effective options for national chlamydia control strategies. It is directed primarily at policy advisors but should also be useful for programme managers and experts in sexual health.
more
La récente augmentation du nombre de cas de microcéphalie et d’autres troubles neurologiques potentiellement associés à une infection à virus Zika a engendré une recrudescence des demandes de dépistage en laboratoire de cette infection. Les groupes prioritaires pour un test de diagnostic d...oivent être constitués de personnes symptomatiques et de femmes enceintes asymptomatiques potentiellement exposées au virus Zika.
Ce document fournit des indications sur les stratégies actuelles de dépistage de l’infection à virus Zika. Il sera revu et actualisé à mesure que des informations supplémentaires deviendront disponibles.
more
Tema 8.22 da agenda provisória
Washington, D.C., EUA, 23 a 27 de setembro de 2018
CD56/INF/22 31 de agosto de 2018
Original: inglês/espanhol
WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i...n randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy.
more
Washington, D.C., EUA, del 26 al 30 de septiembre del 2016
Punto 4.10 del orden del día provisional
CD55/14 8 de julio del 2016
Original: inglés
Training for Health Care Providers
Facilitators’ Manual
Product:BDFACSCountTM InstrumentSystemwithFACSCountTM ControlKitandBD FACSCountTM CD4ReagentKit(AbsoluteandPercentageCD4+Counts)
Number: PQDx 0133-045-00
0133-045-00 WHO
PQDx PR
June/2016, version 2.0